期刊文献+

乳头状甲状腺癌抑癌基因TSHR、P16和RAS启动子甲基化研究 被引量:12

Study on the promoter hypermethylation of TSHR, P16, and RAS genes in human papillary thyroid carcinoma
原文传递
导出
摘要 目的研究促甲状腺激素受体(TSHR)、P16和RAS3个抑癌基因在乳头状甲状腺癌的表达,分析其启动子甲基化与肿瘤发生的关系。方法对50例乳头状甲状腺癌组织和32例对照组织(20例结节性甲状腺肿,12例甲状腺腺瘤)提取RNA后,以RT—PCR检测3个抑癌基因mRNA的表达情况,采用甲基化PCR(MSP)检测上述组织中3个抑癌基因启动子区甲基化的情况,并对3个抑癌基因甲基化和未甲基化的组织随机进行测序。结果50例乳头状甲状腺癌组织中,有34例(68.0%)TSHR基因、27例(54.0%)P16基因、30例(60.0%)RAS基因启动子发生了甲基化;32例对照组织中,有7例(21.9%)TSHR基因、5例(15.6%)P16基因、10例(31.3%)RAS基因启动子发生了甲基化;乳头状甲状腺癌组TSHR、P16、RAS基因启动子甲基化率均显著高于对照组(均P〈0.05)。TSHR、P16和RASmRNA在乳头状甲状腺癌中的表达量明显低于对照组织(0.41±0.11对0.63±0.08,0.51±0.17对0.72±0.22,0.56±0.10对0.67±0.16,均P〈0.05)。经DNA测序证实,3个抑癌基因启动子发生甲基化的其CpG岛碱基未发生改变,仍为CG;未发生甲基化的碱基由CG变为TG。结论3个抑癌基因启动子甲基化与乳头状甲状腺癌的发生和发展均相关。 Objective To study the expressions of the tumor suppressor gene TSH receptor(TSHR) ,P16, and RAS in papillary thyroid carcinoma (PTC) , and the correlation between the occurrence of tumor and the aberrant promoter hypermethylation of three tumor suppressor genes. Methods RT-PCR was used to detect the mRNA expression of three tumor suppressor genes in tissues of 50 cases of PTC,20 cases of nodular goiter,and 12 cases of thyroid adenoma. The promoter methylation status of three tumor suppressor genes was examined by methylation-specific PCR technique(MSP). Gene sequencing was used to test if the hypermethylation existed in the promoter of three tumor suppressor genes. Results In 68.0% (34/50)TSHR gene,54.0% (27/50)P16 gene,and 60.0% (30/50) RAS gene in PTCs, hypermethylation in promoter region was detected, the respective results 21.9% (7/32), 15.6% (5/32), and 31.3% ( 10/32 )were found in control tissues. The rates of the three genes with promoter hypermethylation in PTC were significantly higher than those in control tissues( all P〈0.05 ). The mRNA expressions of TSHR,P16,and RAS were significantly lower in PTC than those in control tissues (0.41± 0.11 vs0.63±0.08,0.51±0. 17 vs 0.72±0.22,0.56±0. 10 vs 0.67±0. 16, all P〈0.05). The sequencing confirmed that there was CG to TG transmission in the promoters of three tumor suppressor genes. Conclusions The methylation of three tumor suppressor genes in promoter region is a common molecule event and may be involved in the genesis and development of human PTC.
出处 《中华内分泌代谢杂志》 CAS CSCD 北大核心 2010年第5期381-384,共4页 Chinese Journal of Endocrinology and Metabolism
基金 深圳市科技局资助项目(200702032)
关键词 乳头状甲状腺癌 甲基化 促甲状腺素受体 P16 RAS 启动子 Papillary thyroid carcinoma Methylation TSHR P16 RAS Promoter
  • 相关文献

参考文献12

  • 1Das PM,Singal R.DNA methylation and cancer.J Clin Oncol,2004,22:46324642.
  • 2Xing M,Usadel H,Cohen Y,et al.Methylation of the thyroid-stimulating hormone receptor gene in epithelial thyroid tumors-a marker of malignancy and a cause of gene silencing.Cancer Res,2003,63:2316-2321.
  • 3Xing M,Cohen Y,Mambo E,et al.Early occurrence of RASSF1A hypermethylation and its mutual exclusion with BRAF mutation in thyroid tumorigenesis.Cancer Res,2004,64:1664-1668.
  • 4Boltze C,Zack S,Quednow C,et al.Hypermethylation of the CDKN2/ pl6 INK4 A promoter in thyroid carcinogenesis.Pathol Res Pract,2003,199=399404.
  • 5Smith JA,Fan CY,Zou C,et al.Methylation status of genes in papillary thyroid carcinoma.Arch Otolaryngol Head Neck Surg,2007,133:1006-1011.
  • 6Schagdarsurengin U,Gimm O,Dralle H,et al.CpC island methylation of tumor-related promoters occurs preferentially in undifferentiated carcinoma.Thyroid,2006,16:633-642.
  • 7Schagdarsuregin U,Gimm O,Hoang-Vu C,et al.Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.Cancer Res,2002,62:3698-3701.
  • 8Byun DS,Lee MG,Chae KS,et al.Frequent epigenetic inactivation of RASSF1A by aberrant promoter hypermethylation in human gastric adenocarcinoma.Cancer Res,2001,61:7034-7038.
  • 9李咏梅,曹芳,曹新.乳腺癌RASSF1A基因表达及启动子区甲基化研究[J].南京医科大学学报(自然科学版),2006,26(7):496-500. 被引量:9
  • 10李敏,黄在菊,董卫红,李晓艳,王晓翊,贺晓红,王瀚,王泽华.卵巢上皮性癌组织中p16INK4A基因表达缺陷的意义及其与甲基化的关系[J].中华妇产科杂志,2006,41(6):408-412. 被引量:8

二级参考文献22

  • 1高云霞,关明,张万忠,吕元.胶质瘤患者RASSF1A基因转录表达和启动子区甲基化的研究[J].中华检验医学杂志,2004,27(7):427-430. 被引量:13
  • 2甄林林,武正炎,范萍,王萱仪.散发性乳腺癌患者BRCA1基因突变检测[J].南京医科大学学报(自然科学版),2005,25(10):693-696. 被引量:5
  • 3SambrookJ FritschEF ManiatisT eds.金冬雁 黎孟枫 译.分子克隆实验指南.第2版[M].北京:科学出版社,1996.463-468.
  • 4Agathanggelous A,Honorio S,Macartney DP,et al.Methylation associated inactivation of RASSF1A from region 3p21.3 in lung,breast,and ovarian tumors[J].Oncogene,2001,20(9):1509-1518
  • 5Lee MG,Kim HY,Byun DS,et al.Frequent epigenetic inactivation of RASSF1A in human bladder carcinoma[J].Cancer Res,2001,61(9):6688-6692
  • 6Burbee DG,Forgacs E,Zochbauer MS,et al.Epigenetic inactivation of RASSF1A in lung and breast cancers malignant phenotype suppression[J].J Natl Cancer Inst,2001,93(9):691-699
  • 7Dammann R,Yang G,Pfeifer GP,et al.Hypermethy-lation of the CpG island of Ras association domain family 1A (RASSF1A),a putative tumor suppressor gene from the 3p21.3 locus,occurs in a large percentage of human breast cancer[J].Cancer Res,2001,61 (13):3105-3109
  • 8Dammann R,Li C,Yoon JH,et al.Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3[J].Nat Genet,2000,25(3):315-319
  • 9Herman JG,Graff JR,Myohanen S,et al.Methylationspecific PCR:a novel PCR assay for methylation status of CpG island[J].Proc Natl Acad Sci SA,1996,93(9):9821-9826
  • 10Honorio S,Agathanggelous A,Schuerman M,et al.Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients[J].Oncogene,2003,22(2):147-150

共引文献11

同被引文献114

  • 1王红卫,洪涛,刘江华,曹仁贤,文格波.人甲状腺乳头状癌高表达基因片段筛选与克隆[J].中华内分泌代谢杂志,2004,20(5):464-466. 被引量:6
  • 2黄平,李德祥,张莹.甲状腺肿瘤中p16基因甲基化及p16蛋白的表达[J].实用肿瘤杂志,2006,21(1):49-51. 被引量:5
  • 3彭正良,曹仁贤,文格波,刘江华,文芳.甲状腺乳头状癌组织中p16基因甲基化的研究[J].现代肿瘤医学,2006,14(12):1501-1503. 被引量:8
  • 4Elaraj DM, Clark OH. Changing management in patients with papillary thyroid cancer. Curr Treat Options Oncol, 2007, 8:305- 313.
  • 5Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol hnaging, 2008, 35 : 1941-1959.
  • 6Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid, 2009, 19: 1167- 1214.
  • 7Van Nostrand D, Wartofsky L. Radioiodine in the treatment of thyroid cancer. Endocrinol Metab Clin North Am, 2007, 36:807-822.
  • 8Meier DA, Brill DR, Becker DV, et al. Procedure guideline for therapy of thyroid disease with iodine-131. J Nucl Med, 2002, 43: 856-861.
  • 9Brewer G,Dick RD,Grover DK,et al.Treatment of metastatic cancer with tetrathiomolybdate,an anticopper,antiangiogenic agent:phase Ⅰ study.Clin Cancer Res,2000,6:1-10.
  • 10Brummelkamp TR,Bernards R,Agami R.A system for stable expression of short interfering RNAs in mammalian cells.Science,2002,296:550-553.

引证文献12

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部